Sat Kartar Life Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 209 Cr.
- Current Price ₹ 132
- High / Low ₹ 220 / 110
- Stock P/E 11.0
- Book Value ₹ 55.1
- Dividend Yield 0.53 %
- ROCE 35.6 %
- ROE 26.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| 163 | 201 | 224 | |
| Sales growth | +23% | +27% | |
| 149 | 176 | 195 | |
| Operating Profit | 14 | 25 | 29 |
| OPM % | 9% | 12% | 13% |
| 1 | 2 | 1 | |
| Interest | 1 | 1 | 0 |
| Depreciation | 1 | 3 | 4 |
| Profit before tax | 13 | 23 | 25 |
| Tax % | 25% | 26% | |
| 10 | 17 | 19 | |
| EPS in Rs | 6.24 | 10.86 | 12.08 |
| Dividend Payout % | 11% | 6% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|
| Equity Capital | 16 | 16 | 16 |
| Reserves | 36 | 52 | 71 |
| 6 | 2 | 2 | |
| 7 | 15 | 14 | |
| Total Liabilities | 65 | 85 | 103 |
| 6 | 12 | 14 | |
| CWIP | 0 | 1 | 0 |
| Investments | 0 | 0 | 1 |
| 58 | 72 | 89 | |
| Total Assets | 65 | 85 | 103 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| -5 | 0 | |
| -0 | -9 | |
| 34 | -1 | |
| Net Cash Flow | 28 | -9 |
| Free Cash Flow | -10 | -7 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -13% | 27% |
Ratios
Consolidated / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 13 | 26 |
| Inventory Days | 185 | 264 |
| Days Payable | 170 | 298 |
| Cash Conversion Cycle | 29 | -7 |
| Working Capital Days | 31 | 58 |
| ROCE % | 36% |
Insights
In beta| Mar 2025 | Mar 2026 | |
|---|---|---|
| Average Ticket Size INR ・Standalone data |
|
|
| Daily Unique Leads leads/day ・Standalone data |
||
| Hospital Bed Capacity beds ・Standalone data |
||
| Number of SKUs SKUs ・Standalone data |
||
| Pincodes Served pincodes ・Standalone data |
||
| Repeat Customer % % ・Standalone data |
||
| South India Revenue Share % ・Standalone data |
||
| Team Strength employees ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Capacity addition
- Sat Kartar Life Limited has informed about proposal for Establishment of new Ayurveda Hospital / Wellness Centre in Jaipur, Rajasthan
-
Updates
- NSE granted in-principle approval for 5,50,000 fully convertible warrants via preferential issue on November 3, 2026.
-
Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
- NSE granted in-principle approval for 5,50,000 convertible warrants via preferential issue on November 3, 2026.
-
Capacity addition
- Signed LOI for 25-bed Lucknow hospital-cum-therapy centre; ₹1 crore investment, operational by February 2027.
-
Analysts/Institutional Investor Meet/Con. Call Updates
- Submitted H1 FY27 earnings call transcript; revenue rose 26.4% to ₹113.9 crore, PAT ₹9.25 crore.
Concalls
-
Oct 2026Transcript PPT REC
-
May 2026Transcript PPT
-
May 2026PPT
-
Nov 2025Transcript
-
Nov 2025Transcript PPT REC
-
Oct 2025PPT
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.